Verrica Pharmaceuticals Inc. - 10-Q Filing
Verrica Pharmaceuticals Inc. filed its Q1 2026 Form 10-Q reporting $5,023 thousand in total revenue (up from $3,439 thousand in the same period last year), driven by product revenue of $4,290 thousand and license/collaboration revenue of $733 thousand. The company reported a net loss from operations of $9,715 thousand due to higher operating expenses ($14,738 thousand) compared to total revenue.
Tickers: $VRCA